Isunakinra
drugOn this page
Also known as EBI-005
Summary
Isunakinra (CHEMBL3545190) is a phase-3 clinical-stage unknown; indicated across 3 conditions including atopic conjunctivitis and dry eye syndrome.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 3 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3545190 |
| Name | Isunakinra |
| Type | Unknown |
| Max phase | 3 |
Also known as: EBI-005, Isunakinra, ISUNAKINRA
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| Interleukin-1 receptor, type I | Inhibition | 10.52 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| atopic conjunctivitis | 3 | MONDO:0005642 | EFO:0007141 |
| dry eye syndrome | 3 | MONDO:0006733 | EFO:1000906 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| PHASE1/PHASE2 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02405039 | PHASE3 | UNKNOWN | Study of EBI-005 in Dry Eye Disease (DED) |
| NCT02492321 | PHASE3 | COMPLETED | A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis |
| NCT06634875 | PHASE2 | RECRUITING | Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) |
| NCT04121442 | PHASE1/PHASE2 | COMPLETED | Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: atopic conjunctivitis, dry eye syndrome